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Abstract This study reports 21 IVF cases with excessive ovarian response, who received gonadotrophin-releasing hormone agonist
(GnRHa) triggering for ﬁnal oocyte maturation, followed by a human chorionic gonadotrophin (HCG)-based, progesterone-free, luteal
support, individually timed (‘luteal coasting’) according to endogenous luteal progesterone concentrations. One patient developed
a brief early-onset moderate ovarian hyperstimulation syndrome (OHSS) condition. Six clinical pregnancies were achieved, two of
which have resulted in live births thus far. To further individualize the luteal phase support post GnRHa trigger, the same principle
that holds for follicular coasting, used in the context of OHSS prevention, may be valid. Monitoring luteal progesterone concentra-
tions from the day of oocyte retrieval, and administering a bolus of HCG (1500 IU) when the concentration drops signiﬁcantly, seems
to facilitate fresh embryo transfer, even in patients with excessive ovarian responses.
© 2015 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
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Introduction
After the initial ﬁndings of poor reproductive outcome when
a standard luteal phase support was used in relation to
gonadotrophin-releasing hormone agonist (GnRHa) trigger
(Humaidan et al., 2005; Kolibianakis et al., 2005), the sub-
sequent development of modiﬁed luteal phase support poli-
cies – either human chorionic gonadotrophin (HCG) rescue,
or intensive steroid rescue (reviewed in Humaidan and
Alsbjerg, 2014) – resulted in a reproductive outcome com-
parable to that of HCG trigger and with the advantage of a
reduction in, if not elimination of, ovarian hyperstimulation
syndrome (OHSS). Thus, GnRHa trigger has become a viable
alternative for the gold standard HCG trigger (Humaidan and
Polyzos, 2014), which is also depicted in a survey indicating
that as many as 36% of IVF GnRH antagonist cycles in Europe
are triggered with GnRHa (IVF Worldwide, 2013).
GnRHa trigger causes a swift luteolysis if not counter-
acted by HCG, which is the reason why modiﬁcations of the
standard luteal phase support are necessary to obtain a good
reproductive outcome after fresh embryo transfer. In this line,
the concept of ‘tailored’, ovarian response-based, luteal
support was suggested. One bolus of HCG (1500 IU) on the day
of oocyte retrieval, followed by a standard luteal phase support
in normal responders (<14 follicles >11mm), yielded good clini-
cal outcomes (Humaidan and Alsbjerg, 2014; Humaidan et al.,
2013). Furthermore, in patients with <12 follicles it has been
shown that two boluses of 1500 HCG only (4 days apart), can
successfully support the full luteal phase after GnRHa trigger,
introducing for the ﬁrst time the exogenous progesterone-
free luteal phase in IVF (Kol et al., 2011). Finally, in OHSS-
risk patients (15–25 follicles > 11 mm), a single bolus of
1500 HCG at the time of oocyte retrieval will result in excel-
lent clinical outcomes and no OHSS development (Humaidan
and Alsbjerg, 2014; Humaidan et al., 2013).
In contrast, for patients with a very high ovarian re-
sponse (>25 follicles >11 mm), the options after GnRHa trigger
so far have been either a segmentation of the cycle, i.e.
‘freeze all’ followed by subsequent frozen–thawed embryo
transfer (Devroey et al., 2011), or intensive luteal steroid
support; however, not even these policies preclude severe
OHSS (Fatemi et al., 2014; Gurbuz et al., 2014).
The above strategies after GnRHa trigger take into account
the cycle-speciﬁc, follicular ovarian responses as the only
factor on which to base the ‘tailoring’, i.e. either fresh trans-
fer and modiﬁed luteal phase support, or segmentation. In
addition, ﬁxed time points are pre-set for the administra-
tion of HCG, i.e. either on the day of GnRHa trigger (‘dual
trigger’, Grifﬁn et al., 2012; Shapiro et al., 2011), on the day
of oocyte retrieval (Humaidan and Alsbjerg, 2014), or 3 days
after oocyte retrieval (Haas et al., 2014). The present pub-
lication introduces the concept of cycle-speciﬁc luteal re-
sponse as the key factor in determining luteal rescue timing.
Previously, follicular phase coasting in the ‘long’ GnRHa
down-regulation protocol has been suggested as a strategy
for OHSS prevention (Delvigne and Rozenberg, 2002). Coast-
ing seeks to induce partial atresia of the developing fol-
licles by withholding gonadotrophin stimulation, while
monitoring oestradiol concentrations, considered to reﬂect
theca- and granulosa-cell function. Using this strategy, HCG
trigger is administered when oestradiol concentrations
drop below a certain cut-off point (Abdallah et al., 2010),
reﬂecting partial demise of the developing follicles, decreas-
ing the burden of multiple corpura lutea formation that
follows.
The luteolysis pattern after GnRHa trigger has been de-
scribed, showing that on day 1 after trigger circulating pro-
gesterone concentrations are comparable, regardless of
whether HCG or GnRHa was used for trigger. In contrast, pro-
gesterone concentrations return to baseline 5 days after GnRHa
trigger, reﬂecting complete luteolysis by this day (Fatemi
et al., 2013).
To further individualize the luteal phase support in OHSS
high-risk patients, having a fresh transfer after GnRHa trigger,
the same principle that holds for follicular phase coasting might
be valid during the luteal phase. In other words, monitoring
progesterone concentrations, and administering the HCG luteal
phase rescue bolus when progesterone concentrations drop
signiﬁcantly.
The following case series explore, for the ﬁrst time, the
above-mentioned novel approach.
Materials and methods
Patients
The ﬁles of 21 consecutive patients treated at the Rambam
IVF unit from April 2014 to April 2015 were summarized.
Ovarian stimulation was performed using highly puriﬁed go-
nadotropin (Menopur, Ferring) with a starting dose of 150 IU
daily, followed by daily injections of a GnRH antagonist
0.25 mg (Cetrotide, Merck Serono) once the leading follicle
reached a size of ≥14 mm in diameter. Patients were con-
sidered at high risk of developing severe OHSS having either
an oestradiol > 12,000 pmol/l or ≥15 follicles of more than
12 mm in diameter on the trigger day (day −2) (Humaidan
et al., 2013). All patients were triggered with a bolus of 0.2 mg
triptorelin (Decapeptyl, Ferring) when ≥3 follicles were
≥17mm in diameter. Oocyte retrieval was performed 36 h later
(day 0). Daily measurement of oestradiol, progesterone and
LH was initiated 48 h post oocyte retrieval (day +2) until it
was decided to administer the HCG bolus. In most patients,
no more blood tests were taken after the HCG bolus, in four
patients mid-luteal progesterone was measured to ascer-
tain that the 1500 HCG bolus maintained adequate proges-
terone during the window of implantation.
Embryo transfer was performed on day +2 or +3 post oocyte
retrieval.
Luteal support
Since it is assumed that decreasing luteal progesterone con-
centrations reﬂect luteolysis, luteal support with a single bolus
of HCG (1500 IU) was given when progesterone concentra-
tion decreased below 30 nmol/l. No further luteal support was
given. A pregnancy test was performed 14 days post oocyte
retrieval (day +14), including oestradiol and progesteronemea-
surements; vaginal ultrasound 1 month after embryo trans-
fer ascertained a viable pregnancy. Data are given as
mean ± SD.
The study was approved by the Rambam Health Care Centre
Institutional Review Board on 11 June 2015.
748 S Kol et al.
Results
Patients’ demographics are given in Table 1. Stimulation
details are given in Table 2.
Luteolysis kinetics and luteal support timing
The majority of patients (12) received the 1500 IU HCG bolus
on day +3. In one patient a ‘quick’ luteolysis resulted in day
+2 bolus. Five patients received the 1500 IU HCG bolus on day
+4. In three patients ‘slow’ luteolysis was observed, leading
to the rescue bolus of HCG being administered on either day
+5, +7, or +8.
While progesterone concentrations (nmol/l) decreased from
day +2 to day +3 (63.2 ± 31.3 and 38.3 ± 35.7, respectively),
oestradiol concentrations (pmol/l) did not change (3794 ± 1770
and 3,738 ± 2,454, respectively). Progesterone and oestra-
diol concentrations on the day of the HCG bolus were reduced
to 38% ± 19 and 87% ± 46, respectively, of the concentra-
tions on day +2.
Importantly, LH secretion (IU/l) was not eliminated by a
single 0.2 mg GnRHa bolus. In fact, its concentrations re-
mained fairly constant in the early luteal phase (1.56 ± 0.9
and 2.4 ± 1.3 for day +2 and day +3, respectively).
Another patient intended to be included in the current
cases series was monitored per the protocol; however, pro-
gesterone concentrations remained >190 nmol/l during the
luteal phase, and so no rescue HCG bolus was given. There-
fore this patient was excluded from this report. Interest-
ingly, an ongoing pregnancy was achieved.
HCG-driven luteal rescue
Mid-luteal phase (7–8 days post oocyte retrieval, implanta-
tion window) progesterone was 140 ± 42 nmol/l (n = 4).
In ongoing pregnancies, day +14 progesterone concentra-
tions were >190 nmol/l in all cases, oestradiol =
10,304 ± 5048 pmol/l.
OHSS
One patient who received the HCG bolus on day +2 devel-
oped a brief early onset moderate OHSS condition, charac-
terized by large ovaries, abdominal discomfort and moderate
amounts of free pelvic ﬂuid.
Reproductive outcome
So far two pregnancies resulted in live births, while another
four pregnancies are presently ongoing. Table 3 summa-
rizes the reproductive outcome so far. Of the six clinical preg-
nancies, 1, 3 and 2 were achieved after HCG boluses on day
+2, +3 and +4, respectively. Three ‘biochemical’ pregnan-
cies were observed (deﬁned as rising serum HCG concentra-
tions from day +14 onwards, followed by decreasing
concentrations after HCG boluses on day +5, +7 and +8).
Discussion
To the best of the present authors’ knowledge, the herein de-
scribed case series is the ﬁrst attempt to further tailor, or
individualize, an HCG-based luteal phase support after GnRHa
trigger and fresh transfer in OHSS high-risk patients. None of
the patients developed any OHSS in need of hospitalization
– importantly, no late-onset OHSS was seen.
The basic principle of this new concept – ‘luteal coast-
ing’ – is to closely monitor the individual luteolytic process
after GnRHa trigger in terms of circulating progesterone con-
centrations, and to intervene with an HCG rescue bolus when
the process is ﬁrmly underway, but well before total and ir-
reversible luteolysis has occurred.
While segmentation is certainly an option in cases of high
ovarian response (Devroey et al., 2011), luteal coasting as sug-
gested herein may be more acceptable for both patients and
clinicians. Importantly, there may be regional, legal, eco-
nomical and ethical considerations that do not facilitate
cryopreservation. Moreover, although the success rate after
cryopreservation has increased signiﬁcantly worldwide, still
not all IVF units have successful cryopreservation pro-
grammes at their disposal. Finally, not even the segmenta-
tion protocol will eliminate severe OHSS in the OHSS high-
risk patient (Fatemi et al., 2014).
Based on limited previous data, complete functional
luteolysis seems to be reached within 5 days after GnRHa
Table 1 Main demographic parameters of
the study population.
Age (years) 26.4 ± 4.9
Indication
Unexplained 4
Male 14
Mechanical 2
PCO 1
BMI 23.9 ± 3.8
BMI = body mass index; PCO = polycystic ovaries.
Table 2 Stimulation characteristics and embryology data.
Stimulation (days) 9.8 ± 2.3
FSH (units) 1570 ± 633
Follicles >12 mm 18.0 ± 4.8
Oestradiol trigger day (pmol/l) 16,839 ± 3919
Oocytes retrieved 16.9 ± 5.4
Fertilizations 8.5 ± 3.7
Embryos transferred 1.86 ± 0.48
Embryos frozen 3.1 ± 2.6
Day 1500 IU HCG administered 3.7 ± 1.4
HCG = human chorionic gonadotrophin.
Table 3 Reproductive outcome.
Positive HCG n, (%) 9/21 (43)
Clinical pregnancy n, (%) 6/21 (29)
Early pregnancy loss n, (%) 3/9 (33)
HCG = human chorionic gonadotrophin.
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trigger (Fatemi et al., 2013). However, the present data
clearly indicate that there is a wide variability between
patients as to luteolysis kinetics. Although most patients
received the HCG bolus between day +2 and +4, three pa-
tients had a relatively slow luteolytic process, receiving the
bolus on day +5, +7 and +8. This ﬁnding reﬂects signiﬁcant
population variability in the context of the luteolytic process
kinetics, and underlines the basic concept of careful indi-
vidualized follow-up when deciding the timing of the HCG
rescue bolus. Although more research is needed, according
to our experience, so far, we suggest that as soon as the
progesterone concentration drops below 30 nmol/l, an HCG
bolus should be administered. This cut-off point was chosen
based on previous research describing the luteal progester-
one threshold concentration in a natural cycle (Hull et al.,
1982; Yovich et al., 1986). However, further research is
needed, since one cannot rule out the possibility of inad-
equate luteal support, using this concentration as the cut-
off. Although the reported series is too small to draw
meaningful conclusions regarding the reproductive outcome,
the relatively high pregnancy loss (33%) noted in this small
series could be related to inadequate luteal support. One of
the limitations of this study is the lack of a control group.
Therefore, we are not able to conclude if this novel ap-
proach is better than the ﬁxed administration of 1500 IU of
HCG on the morning of oocyte retrieval.
There is a notable difference between progesterone and
oestradiol kinetics during the luteolytic process. Progester-
one concentrations sharply decrease in the early luteal phase
(day 2 to day 3), while oestradiol concentrations stay the same.
Similarly, on the day of HCG bolus progesterone concentra-
tion is only 38% of its day 2 peak, while oestradiol concen-
tration decreases only slightly (87%).
We speculate that genetic differences may explain wide
variability in post GnRHa trigger luteolysis kinetics, as well
as OHSS post agonist trigger (Fatemi et al., 2014; Gurbuz et al.,
2014), or frequent severe early OHSS following GnRHa trigger
with the addition of 1500 IU HCG on retrieval day (Seyhan
et al., 2013). Therefore, we suggest that these differences
might be best dealt with using an individualized post GnRHa
trigger follow-up of the luteolytic process in order to facili-
tate a fresh transfer and minimize the OHSS risk.
The novel concept of ‘luteal coasting’ after GnRHa trigger
offers two advantages. Firstly, it seems to allow fresh trans-
fer in high-risk OHSS patients. Secondly, it paves the way
for the exogenous progesterone-free luteal phase in IVF, a
concept previously suggested (Humaidan and Alsbjerg, 2014;
Kol et al., 2011), and which frees the patient of either
leaky vaginal discharge caused by vaginal administration of
progesterone, or painful daily intramuscular progesterone
injections. Recently, a subcutaneous daily progesterone for-
mulation (Baker et al., 2014) was brought to the market, to
be used from the day of oocyte retrieval and up to 10 weeks
if pregnancy is achieved. Although it is not the intention of
this communication to conduct a cost-analysis, it seems rea-
sonable to assume that an additional three to four
progesterone measurements are more cost-effective and
patient friendly compared with 70 subcutaneous progester-
one injections.
Deferring the early luteal phase HCG rescue bolus from the
day of trigger or retrieval to 2–4 days later, brings it closer
to the day of implantation, which per se might increase the
receptivity of the endometrium (Tesarik et al., 2003). Al-
though the early luteal phase progesterone drops precipitously
with this concept, it recovers quickly after the rescue bolus
towards the mid-luteal phase, reﬂecting partial rescue of the
corpora luteae. Importantly, in all ongoing clinical pregnan-
cies high progesterone concentration on the day of preg-
nancy test (>190 nmol/l) clearly shows that any additional
exogenous progesterone is redundant.
As mentioned a limitation of the current report is obvi-
ously that a control group was not part of the case series.
Moreover, one might suggest that for this category of high-
risk OHSS patients a freeze-all policy should be adopted.
However, the primary intention was to perform an explor-
ative case series, using a novel concept rather than a ran-
domized controlled trial; furthermore, not even a freeze-
all policy will eliminate OHSS development in the high-risk
OHSS patient (Fatemi et al., 2014; Gurbuz et al., 2014), and
as previously mentioned, there are regional, legal, economi-
cal and ethical considerations that do not support the use of
cryopreservation.
In summary, a case series of HCG-based tailored luteal
phase support in OHSS high-risk patients undergoing fresh
transfer after GnRHa trigger is described. No further exog-
enous luteal support was administered, and the endogenous
early luteal progesterone concentration was used to decide
when to administer the HCG rescue bolus. Clearly, the present
results need to be corroborated in a larger group of IVF pa-
tients at risk of OHSS development – if possible adding a
control group of freeze-all patients. However, this novel luteal
tailoring concept after GnRHa trigger and fresh transfer might
help cover the full scope of ovarian responses.
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